Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature

Journal of Market Access and Health Policy

Volumn 1, Issue 1, 2013, Pages

  Murteira, Susana ^a,b   Ghezaiel, Zied ^c   Karray, Slim ^c   Lamure, Michel ^a  

^a UNIVERSITÉ DE LYON   (France)

^b Lundbeck   (France)

^c CREATIV CEUTICAL   (France)

Author keywords

classification; combination; lifecycle management; market access; reformulation; repositioning; repurposing; taxonomy

Indexed keywords

EID: 85038651316     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v1i0.21131     Document Type: Article

References (33)

1. LiYY, JonesSJM. Drug repositioning for personalized medicine. Genome Med. 2012; 4: 27.
2. LekkaE, DeftereosSN, PersidisA, PersidisA, AndronisC. Literature analysis for systematic drug repurposing: a case study from Biovista. Drug Discov Today Ther Strateg. 2012; 8: 103–8.
3. PersidisA. The benefits of drug repositioning. Drug Discov World. 2011; 12: 9–12.
4. SleighSH, BartonCL. Repurposing strategies for therapeutics. Pharm Med. 2010; 24: 151–9.
5. SmithRB. Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg. 2011. 8:131–7.
6. Business Insights reports. Successful strategies for drug repositioning: low-risk approaches to indication expansion and lifecycle extension for established molecules. London (UK): Business Insights. 2011; 101. Report No.: BI00050–002.
7. PadhyBM, GuptaYK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011; 57: 153–60.
8. HoltRIG, BarnettAH, BaileyCJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Met. 2010; 12: 1048–57.
9. TomerG. Prevailing against cost-leader competitors in the pharmaceutical industry. J Generic Med. 2008; 5: 305–14.
10. HorbalJM, BernsteinJA. Azelastine HCL: a review of the old and new formulations. Clin Med Insights Ther. 2010; 2: 427–37.
11. TranHT, KlugerJ, ChowMSS. Focus on IV amiodarone: a new formulation for acute arrhythmia treatment. Formulary. 1995; 30: 509–19.
12. HuskampHA, BuschAB, DominoME, NormandSLT. Antidepressant reformulations: who uses them, and what are the benefits?. Health Aff. 2009; 28: 734–45.
13. KingmaI, LudwinD, DandavinoR, WolffJL, LoertscherR, Beauregard-ZollingerL. Economic analysis of Neoral in de novo renal transplant patients in Canada. Clin Transplant. 1997; 11: 42–8.
14. ClayPG, TaylorTAH, GlarosAG, McRaeMP, WilliamsC, McCandlessD. “One pill, once daily”: what clinicians need to know about Atripla (trademark). Ther Clin Risk Manag. 2008; 4: 291–302.
15. BreretonN, BodgerK, KammMA, HodgkinsP, YanS, AkehurstR. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ. 2010; 13: 148–61.
16. GuerriniR. Valproate as a mainstay of therapy for pediatric epilepsy. Pediatr Drugs. 2006; 8: 113–29.
17. InsaR. Drug repositioning: filling the gap. EBR Eur Biopharm Rev. 2010;(Summer):; 44–8.
18. TobinickEL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009; 22: 119–25.
19. SirotaM, DudleyJT, KimJ, ChiangAP, MorganAA, Sweet-CorderoA. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011; 3: 96ra77.
20. HuangR, SouthallN, WangY, YasgarA, ShinnP, JadhavA. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011; 3: 80ps16.
21. Von EichbornJ, MurgueitioMS, DunkelM, KoernerS, BournePE, PreissnerR. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 2011; 39: D1060–D6.
22. PawarVK, KansalS, AsthanaS, ChourasiaMK. Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory consideration. Expert Opin Drug Deliv. 2012; 9: 551–65.
23. JinG, FuC, ZhaoH, CuiK, ChangJ, WongSTC. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res. 2012; 72: 33–44.
24. HermannAMM. Drug repositioning: extracting added value from prior R&D investments. Insight pharma reports.
25. Datamonitor reports. Lifecycle management strategies: reformulation: success hinges on delivering significant improvement in disease outcome. USA (NY): Datamonitor; 2012, 30 p. Report No.: HC00246–001.
26. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov. 2002;1: 753–68.
27. Datamonitor reports. Drug repositioning strategies: serendipity by design. USA (NY): Datamonitor. 2008; 97. Report No.: DMHC2400.
28. YuryevA, KotelnikovaE, DaraseliaN. Ariadne's chemeffect and pathway studio knowledge base. Expert Opin Drug Discov. 2009; 4: 1307–18.
29. Duenas-GonzalezA, Garcia-LopezP, HerreraLA, Medina-FrancoJL, Gonzalez-FierroA, CandelariaM. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer. 2008; 7: 82.
30. Should (black down triangle) dabigatran replace warfarin for stroke prevention in AF?. Drug Ther Bull. 2011; 49: 114–7.
31. BaldingerSL, ChowMSS. Focus on anticoagulants: Warfarin's new indication for cardiovascular disease and enoxaparin's new indication for knee replacement surgery. Formulary. 1995; 30: 657–76.
32. SchmierJK, CovertDW, RobinAL. First-year treatment patterns among new initiators of topical prostaglandin analogs. Curr Med Res Opin. 2009; 25: 851–8.
33. GuptaSK. Duragesic (registered trademark) D-TRANS (registered trademark), a new matrix delivery system for fentanyl: progress in a new technology. Douleurs. 2005; 6: 105–8.